Scarica l'app Stockscreener
5.64
5.42%
0.29
Dopo l'orario di chiusura:
5.63
-0.010
-0.18%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARDX Giù?
Forum
Previsione
Precedente Chiudi:
$5.35
Aprire:
$5.45
Volume 24 ore:
2.50M
Relative Volume:
0.55
Capitalizzazione di mercato:
$1.38B
Reddito:
$407.32M
Utile/perdita netta:
$-61.60M
Rapporto P/E:
-21.89
EPS:
-0.2576
Flusso di cassa netto:
$-43.98M
1 W Prestazione:
+1.62%
1M Prestazione:
-14.02%
6M Prestazione:
-5.37%
1 anno Prestazione:
+8.67%
Intervallo 1D:
$5.45
$5.73
Intervallo di 1 settimana:
$5.00
$5.73
Portata 52W:
$3.21
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Nome
Ardelyx Inc
Settore
Industria
Telefono
510-745-7047
Indirizzo
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
5.64 | 1.31B | 407.32M | -61.60M | -43.98M | -0.2576 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-09 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-09-03 | Ripresa | Raymond James | Strong Buy |
| 2025-06-18 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-02 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-03-07 | Ripresa | Ladenburg Thalmann | Buy |
| 2025-03-04 | Iniziato | BTIG Research | Buy |
| 2024-11-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-07-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | Iniziato | Leerink Partners | Outperform |
| 2023-12-18 | Iniziato | Raymond James | Strong Buy |
| 2023-09-07 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-25 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-11-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | Downgrade | Jefferies | Buy → Hold |
| 2021-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-23 | Iniziato | Wedbush | Outperform |
| 2021-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-20 | Ripresa | Citigroup | Buy |
| 2020-02-18 | Ripresa | Jefferies | Buy |
| 2020-02-12 | Iniziato | Citigroup | Buy |
| 2020-02-10 | Iniziato | Cowen | Outperform |
| 2019-04-08 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-24 | Iniziato | Jefferies | Buy |
| 2018-03-19 | Ripresa | Leerink Partners | Outperform |
| 2017-11-29 | Reiterato | Citigroup | Buy |
| 2017-11-22 | Reiterato | Ladenburg Thalmann | Buy |
| 2017-10-17 | Ripresa | Leerink Partners | Outperform |
| 2016-03-31 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-03-09 | Iniziato | Cantor Fitzgerald | Buy |
| 2016-03-03 | Iniziato | Citigroup | Buy |
Mostra tutto
Ardelyx Inc Borsa (ARDX) Ultime notizie
Piper Sandler Maintains a Hold Rating on Ardelyx (ARDX) - MSN
Ardelyx's post-earnings decline attributed to concerns over Ibsrela outlook - MSN
Ardelyx gains after insider purchase, LPGA marketing deal - MSN
ARDX SEC FilingsArdelyx 10-K, 10-Q, 8-K Forms - Stock Titan
ARDX stock is down pre-market after Q4 earnings miss, so why did this firm just hike price target by 80%? - MSN
Can Ardelyx Inc stock outperform in a bear market2026 Short Interest & Stepwise Trade Execution Plans - baoquankhu1.vn
ARDX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Insider Selling: Ardelyx (NASDAQ:ARDX) CEO Sells 41,666 Shares of Stock - MarketBeat
Raab, Ardelyx CEO, sells $243k in ARDX stock By Investing.com - Investing.com Canada
Raab, Ardelyx CEO, sells $243k in ARDX stock - Investing.com
Ardelyx (ARDX) CEO exercises options, sells 41,666 shares under plan - Stock Titan
Ardelyx, Inc. Opens with 8.38% Gain, Contrasting Recent Performance Trends - Markets Mojo
Ardelyx, Inc. Hits Day High with Strong 14.49% Intraday Surge - Markets Mojo
ARDX Stock Price, Quote & Chart | ARDELYX INC (NASDAQ:ARDX) - ChartMill
Will Ardelyx’s (ARDX) IBSRELA Data Shift Its Competitive Position In IBS-C Treatments? - simplywall.st
Leerink Maintains Outperform on Ardelyx, Inc (ARDX) March 12, 2026 - Meyka
Leerink Partners reiterates Ardelyx stock rating on pipeline progress - Investing.com
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award - The Manila Times
Five kidney disease advocates honored for decades of patient support - Stock Titan
Breakout Move: How does Ardelyx Inc correlate with Nasdaq2026 Highlights & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Ardelyx Touts IBSRELA’s 73% Growth, Reaffirms $1B 2029 Goal and Details CIC Phase III Plan - MarketBeat
Ardelyx at Leerink Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada
ARDX: IBSRELA targets $1B sales by 2029, with pipeline and commercial growth fueled by strong execution - TradingView
Assessing Ardelyx (ARDX) Valuation After Recent Share Price Weakness - Yahoo Finance
Ardelyx (ARDX) Valuation Check After Recent Share Price Weakness And Growth Expectations - simplywall.st
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C - The Manila Times
Ardelyx, Inc. Publishes Data Supporting Tenapanor's Rapid and Sustained Relief for IBS-C in Peer-Reviewed Journal - Quiver Quantitative
Ardelyx Announces Publication of a Review Article - GlobeNewswire
Is Ardelyx (ARDX) Pricing In Its Potential After Recent Share Price Weakness - Yahoo Finance
Is Ardelyx (ARDX) Pricing Reflect Its DCF Upside After Recent Share Price Volatility - simplywall.st
Is Ardelyx Inc. (41X) stock bottoming after sell off2026 Buyback Activity & Technical Pattern Based Buy Signals - Naître et grandir
Ardelyx, Inc. (NASDAQ:ARDX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Is Ardelyx’s 2026 IBSRELA Outlook Altering The Investment Case For Ardelyx (ARDX)? - Sahm
Vanguard Group Inc. Boosts Holdings in Ardelyx, Inc. $ARDX - MarketBeat
Ardelyx to Participate in Upcoming Investor Conferences - GlobeNewswire
ARDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Ardelyx (NASDAQ:ARDX) Stock Passes Below 200-Day Moving AverageWhat's Next? - MarketBeat
Ardelyx LPGA Partnership Puts Spotlight On Women’s Digestive Health And Growth - simplywall.st
Assessing Ardelyx (ARDX) Valuation After Strong 2025 Results And 2026 Growth Guidance - simplywall.st
Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership - The Globe and Mail
Revisiting ArdelyxInsider Weekends (NASDAQ:ARDX) - Seeking Alpha
ARDX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Ardelyx, Inc. (ARDX) Investor Outlook: Analysts See A Potential 142% Upside - DirectorsTalk Interviews
Ardelyx goes full swing with the LPGA for IBS-C awareness - Medical Marketing and Media
ARDELYX (NASDAQ: ARDX) CEO Raab sells 41,666 shares after option exercise - Stock Titan
Ardelyx Inc Azioni (ARDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):